title: The promise and pitfalls of monoclonal antibody therapeutics.
abstract: Recent experience has helped to clarify the best ways to use monoclonal antibodies to solve clinical problems. For example, imaging based on tumor antigens, rather than tumor size, will permit early detection of cancer and accurate staging. Blocking receptor-ligand interactions may permit therapeutic intervention in cell growth or function but activity may depend on the choice of an antiligand or antireceptor strategy. Humanized antibodies will achieve greater intensity and duration of therapy, while allowing repeat administration in chronic diseases.
authors.affiliation: Laboratory of Immunoregulation, Division of Allergenic Products and Parasitology, Office of Vaccine Research Center for Biologics, Food and Drug Administration, Bethesda, MD 20892, USA. Berkower@a1.cber.fda.gov
authors.forename: I
authors.initials: I
authors.lastname: Berkower
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D000951:Antigens, Neoplasm; D015195:Drug Design; D006801:Humans; D007136:Immunoglobulins / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D051379:Mice; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology; D012680:Sensitivity and Specificity
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007136:Immunoglobulins; D011994:Recombinant Proteins